Study guide

13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF)

DABT: Diplomate of the American Board of Toxicology Exam

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Study Design Fundamentals

1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration

2 Dose Selection, Controls & Biostatistics in Toxicology

2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data

3 Study Execution, GLP Compliance & Quality Assurance

3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections

4 Executing In Vivo, In Vitro, In Silico & Field Studies

4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization

5 Clinical Pathology & Toxicologic Pathology

5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation

6 Specialized Toxicological Study Endpoints

6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology

7 Toxicokinetics & Biotransformation

7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification

8 Cellular Mechanisms of Toxicity & Organ Pathogenesis

8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity

9 Hazard Identification & Evidence Integration

9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses

10 Mode of Action, AOPs & Non-Cancer Endpoints

10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects

11 Exposure Assessment Methodologies & Quantification

11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF

12 Quantitative Dose-Response Principles & Point of Departure Derivation

12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose

13 Health-Based Guidance Value Derivation & Uncertainty Factors

13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)

14 Risk Characterization for Non-Cancer & Cancer Health Effects

14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization

15 Risk Management, Occupational Exposure Limits & Environmental Standards

15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations

16 Regulatory Frameworks & Product Stewardship

16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH

17 Clinical Toxicology & Medical Management of Poisoning

17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies

18 Environmental, Ecological & Public Health Toxicology

18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation

13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF)

Key Takeaways Explain This Topic AI

EPA default uncertainty factors are often 10-fold each: UFA (interspecies), UFH (intraspecies), UFS (subchronic-to-chronic), UFL (LOAEL-to-NOAEL), and UFD (database); a leftover half-log is recorded as 3.

UFs are multiplied, never added. EPA 2002/IRIS practice often treats a composite of 3,000 as a practical ceiling when four full tens would make 10,000; that ceiling is common practice, not a statute.

UFA and UFH split into toxicokinetic and toxicodynamic halves. EPA often uses about 3 × 3; WHO IPCS interspecies default is 4 (TK) × 2.5 (TD). CSAF and EPA DDEF replace a named half when chemical-specific ratios exist.

After default oral BW^0.75 HED or inhalation HEC dosimetry, residual UFA is typically 3, not a second full 10 on the same TK difference. Human PoDs take UFA = 1.

EPA 2011 oral systemic scaling uses BW^0.75 so mg/kg HED = animal dose × (BWa/BWh)^0.25. FDA 2005 first-in-human conversion uses mg/m2 (BW^0.67; rat Km 6/37 ≈ 0.16). Portal-of-entry lesions do not get the oral 0.75 default.

Last updated: September 2026

Uncertainty factors turn a laboratory dose into a public-health number

Handbook III.C.1 H and III.C.3 G ask you to take a point of departure (PoD) from Chapter 12—a NOAEL, LOAEL, or BMDL, sometimes already converted to a human equivalent dose (HED) or human equivalent concentration (HEC) as in Chapters 11–12—and divide it by factors that cover gaps between that study and the people you are protecting. Independent ExamFinch teaching in this section covers U.S. Environmental Protection Agency (EPA) default uncertainty factors (UFs) , the toxicokinetic (TK) versus toxicodynamic (TD) split of interspecies and intraspecies factors, World Health Organization International Programme on Chemical Safety (WHO IPCS) chemical-specific adjustment factors (CSAFs) , EPA data-derived extrapolation factors (DDEFs) , allometric scaling ( body weight^0.75 versus mg/m² / body weight^0.67 ), and when those defaults still apply after an HED or HEC is already on the table. This material is not an ABT, EPA, WHO, or IPCS product and does not claim official approval, review, or partnership with those bodies.

Domain III.C (dose–response) is 9% of the examination. Items here punish stacking every 10-fold factor that can be named, treating a composite UF of 3,000 as a law Congress wrote, or applying BW^0.75 and a full UFA of 10 to the same interspecies TK difference.

What a UF does

A UF is a unitless divisor . For an oral noncancer value:

RfD = PoD / (UF_composite × MF)

If the PoD is 25 mg/kg-day and the composite UF is 100 , the RfD is 0.25 mg/kg-day . The factor does not convert a 10% extra-risk BMDL into a 0.1% extra-risk BMDL by biology. It does not prove that the true human threshold sits at PoD/100. EPA’s own RfD definition still says the estimate has “uncertainty spanning perhaps an order of magnitude.” A UF is science-policy coverage of a named gap: different species, different humans, shorter studies, a LOAEL instead of a NOAEL, or a thin database.

Modifying factor (MF). Older IRIS write-ups allowed an extra 1 to 10 professional-judgment MF (completeness of the critical study, steepness of the dose–response, or other residual issues not captured by the named UFs). In most modern files MF = 1 . EPA’s 2002 Review of the Reference Dose and Reference Concentration Processes (EPA/630/P-02/002F) encouraged folding leftover judgment into the named UFs, especially UFD , rather than inventing a sixth silent 10. If an item still shows MF = 3, multiply it in; do not ignore it and do not add it to the UFs ( 10 + 3 is wrong; 10 × 3 is right).

UFs are multiplied , never added. UFA = 10 and UFH = 10 is 100 , not 20.

EPA’s default five (often 10 each)

Factor Name Default when the gap is fully present Typical partial value What it covers

UFA Interspecies (animal to human) 10 3 after default HED/HEC, or 3 for one of TK/TD Humans may be more sensitive than the tested species

UFH Intraspecies (human variability) 10 3 when TK or TD is partly quantified; 1 only with strong sensitive-subgroup data The RfD must protect sensitive people, not only the mean adult in the study

UFS Subchronic to chronic 10 3 when duration is intermediate or the effect is not expected to progress The critical study is shorter than the lifetime the RfD claims to cover

UFL LOAEL to NOAEL 10 3 when the LOAEL is mild and closely spaced; 1 if a NOAEL or BMDL is the PoD The PoD is already in the adverse range

UFD Database deficiency 1 to 10 3 is common when one major study type is missing Missing developmental, reproductive, or other studies that could have produced a lower PoD

MF Modifying factor 1 1–10 in older files Residual professional judgment

UFA (interspecies). Default 10 when you start from an animal administered dose with no dosimetric conversion. EPA often splits that 10 into TK and TD , each about a half-log . 10^0.5 ≈ 3.16 , which EPA rounds to 3 when a half-factor is used alone . After BW^0.75 oral HED (EPA 2011) or RfC inhalation HEC (EPA 1994 methods), the TK half is treated as addressed , and residual UFA is typically 3 (remaining TD plus leftover TK). Human epidemiological PoDs take UFA = 1 —there is no animal-to-human jump.

UFH (intraspecies). Default 10 to cover children, elderly people, genetic polymorphisms, disease, and pregnancy. It can be split about 3 TK × 3 TD . EPA 2002 warned against shrinking UFH merely because “adults vary by less than 10.” Reduction needs data on the susceptible group you claim to have covered , not a wish. A Food Quality Protection Act (FQPA) extra 10× for infants and children is an Office of Pesticide Programs statutory overlay on some pesticide risk cups. It is not a sixth default IRIS UF for every industrial chemical.

UFS (duration). A 90-day (subchronic) rodent study supporting a lifetime RfD typically draws UFS = 10 . A 2-year rodent bioassay supporting a chronic RfD draws UFS = 1 . A 6-month or 1-year study, or a subchronic effect that is not expected to worsen with time (some adaptive liver-weight changes), may support UFS = 3 . UFS is not applied because the chemical has a long half-life; that is a TK problem for UFA/UFH or a PBPK model.

UFL (LOAEL). If the PoD is a NOAEL or BMDL , UFL = 1 . If you must start from a LOAEL because no NOAEL was identified, default 10 . A minimal LOAEL (mild, reversible, tightly spaced above a true no-effect region) may support 3 . BMD modeling is how you avoid UFL : the BMDL is already a bound on a defined response, so you do not also take a LOAEL-to-NOAEL 10 on the same endpoint.

UFD (database). A package with chronic, developmental, and reproductive studies and a well-chosen critical effect often gets UFD = 1 . Missing a prenatal developmental or two-generation reproductive study commonly draws 3 . Several missing study types, or a critical effect that looks like the wrong organ because the right study was never run, can draw 10 . UFD is the factor people forget, then double-count by also inflating UFS.

Half-logs and the composite

EPA uses 3 as the stand-in for √10 . Arithmetic consequences:

One leftover half-factor with tens: 10 × 10 × 3 = 300 . Keep the 3 . Do not “round 300 to 100” or to 1,000 .

Two half-factors together are treated as a full log: 3 × 3 is recorded as 10, not 9 . So UFA = 3 , UFH = 10 , UFS = 3 becomes 100 , not 90 .

Never add 10 + 10 + 3 = 23.

Worked composite. Animal BMDL, no HED: UFA = 10 , UFH = 10 , UFS = 1 (chronic study), UFL = 1 (BMDL), UFD = 3 (no developmental study). Composite = 10 × 10 × 3 = 300 .

Same BMDL after BW^0.75 HED : UFA = 3 , UFH = 10 , UFD = 3 → 100 (two 3s counted as 10, times the remaining 10).

Do not pile 10s without thought: the 3,000 practice

Multiplying four full tens gives 10,000 . Five tens give 100,000 . EPA practice does not treat that product as automatic. The 2002 RfD/RfC review recommended limiting the total UF on a chronic reference value to 3,000 . The reason is overlap : duration, database, and LOAEL gaps are not independent of species and human-variability gaps. When four full areas would mathematically be 10,000 , IRIS-style write-ups often combine two areas inside one 10 , leaving a composite of 3,000 .

This 3,000 figure is common IRIS practice and a technical-panel recommendation. It is not a statute. Congress did not enact it. An older file with UF = 10,000 is not “illegal,” and a 2024 assessment that stops at 300 because the database is rich is not “noncompliant with a 3,000 rule.” If the assessor would need more than 3,000 —five independent full tens—the 2002 panel’s logic is that the database is probably too thin to support an RfD at all . The grown-up move is to say no RfD , not to print 0.00001 mg/kg-day from a 28-day LOAEL in one species.

CSAF and DDEF: replace defaults when you have ratios

WHO IPCS (2005) chemical-specific adjustment factors and EPA (2014) data-derived extrapolation factors are the same idea with different initials. When you can measure the TK or TD ratio, you replace that half of the default , not the entire UF stack.

IPCS default interspecies 10 = 4 (TK) × 2.5 (TD) . The 4 is the allometric/TK piece (clearance scaling roughly with BW^0.75 ). The 2.5 is residual TD. That 4 × 2.5 split is not the same as EPA’s 3 × 3 . Mixing “EPA half-log 3” with “IPCS TK 4” on one line without naming the scheme is an item trap.

IPCS default human variability 10 ≈ 3.16 TK × 3.16 TD .

EPA DDEF names: EFAK (interspecies TK), EFAD (interspecies TD), EFHK (human TK), EFHD (human TD). After default oral BW^0.75 or inhalation HEC , EPA’s remaining interspecies default is the TD-ish 3 , not another 4.

How a TK CSAF is built. Pick a dose metric tied to the mode of action ( AUC , Cmax , amount metabolized). Find the animal external dose and the human external dose that produce the same internal metric .

CSAF_AK (or EFAK) = animal_external / human_external for that match.

If the animal PoD is 10 mg/kg-day and a PBPK model says humans reach the same AUC at 2.5 mg/kg-day , EFAK = 10 / 2.5 = 4 . You then apply that 4 instead of the default TK piece. If the HED is already 2.5 , you do not also divide by 4; the conversion is the TK factor, and UFAK = 1 .

Worked AUC ratio (same external mg/kg). At 10 mg/kg , predicted AUC_rat = 20 µg·h/mL and AUC_human = 80 µg·h/mL . Humans experience 80/20 = 4-fold more internal exposure per mg/kg, so they are TK-more sensitive . IPCS-style CSAF_AK = 4 . Times default TD 2.5 → interspecies composite 10 (here the data equal the IPCS TK default; they do not enlarge it). If instead AUC_human = 40 , CSAF_AK = 2 , times 2.5 = 5 , which replaces default 10 for interspecies. If AUC_human = AUC_rat , CSAF_AK = 1 , and only 2.5 (TD) remains— if you trust the metric.

TD CSAFs need a comparable tissue response (in vitro receptor occupancy, red-cell sensitivity, acetylcholinesterase IC50). EPA’s ethylene glycol monobutyl ether IRIS story is the teaching example of PBPK TK plus measured red-cell TD , driving UFAK and UFAD away from 10. You do not need that chemical’s numbers memorized; you need the logic : data replace the named half; they do not license deleting UFH because you liked the PBPK plot.

If humans are less TK-sensitive (higher clearance), CSAF_AK can be < 1 , which increases the HED. Defaults of 10 never go below 1; data can . That is the point of CSAF.

Allometric scaling: BW^0.75 versus mg/m² (0.67)

Physiological rates (clearance, caloric use) often scale closer to body weight^0.75 than to body weight^1. Dose in mg/day then scales with BW^0.75 , so dose in mg/kg-day scales with BW^−0.25 :

HED (mg/kg-day) = animal dose (mg/kg-day) × (BW_animal / BW_human)^0.25

EPA 2011 ( Recommended Use of Body Weight^3/4 as the Default Method in Derivation of the Oral Reference Dose ) uses that 3/4-power default for oral systemic animal-to-human conversion. After it is applied, UFA residual is typically 3 .

Body-surface-area / mg/m² scaling uses exponent 2/3 ≈ 0.67 . Then mg/kg HED scales with (BWa/BWh)^0.33 . FDA 2005 first-in-human guidance (Chapter 12) implements this with Km factors (human 37 , rat 6 , mouse 3 , dog 20 ). Rat mg/kg × 6/37 ≈ 0.16 . That is the FIH/chemotherapy playbook, not the EPA chronic oral RfD playbook.

  • Playbook Exponent on BW for mg/day mg/kg conversion Typical next factor
  • EPA 2011 oral systemic RfD 0.75 × (BWa/BWh) 0.25 Residual UFA ≈ 3
  • FDA 2005 FIH / mg/m² 0.67 × (BWa/BWh) 0.33 , or Km ratio Safety factor often 10 on HED (MRSD), not an RfD
  • IPCS TK default Built into CSAF_AK = 4 Same 3/4 idea Times TD 2.5
  • REACH oral DNEL (rat) Allometric 4 Same family Times remaining 2.5

Worked BW^0.75. Rat 0.25 kg , human 70 kg , animal PoD 10 mg/kg-day .

BWa/BWh = 0.25/70 = 0.003571 .

(0.25/70)^0.25: 0.25^0.25 = 0.7071 , 70^0.25 ≈ 2.893 , ratio 0.7071/2.893 = 0.244 .

HED = 10 × 0.244 = 2.44 mg/kg-day. Using 0.24 as a rounded DAF: 2.4 mg/kg-day .

Apply UFA = 3 and UFH = 10 (chronic NOAEL/BMDL, complete database): composite 30 .

RfD = 2.44 / 30 = 0.081 mg/kg-day.

Wrong double count: HED 2.44 then UFA = 10 and UFH = 10 → 2.44/100 = 0.024 mg/kg-day. That reapplies TK already spent in the 0.75 exponent.

Wrong skip: no HED, 10 / (10 × 10) = 0.10 mg/kg-day. Different number, older administered-dose style; if the item says EPA 2011 HED was used, this is incorrect.

FDA 0.67 on the same 10 mg/kg rat dose: 10 × (6/37) = 1.62 mg/kg-day . That 1.62 is an HED for FIH , not an RfD until someone applies a different factor stack. Using 1.62 inside an IRIS RfD as if it were the 2011 DAF is mixing playbooks.

Mouse DAF check. Mouse 0.025 kg , human 70 kg : (0.025/70)^0.25 ≈ 0.138 . Animal PoD 10 mg/kg-day → HED ≈ 1.38 mg/kg-day . ICH Q3C F1 = 12 for mouse is a surface-area species factor (1/12 ≈ 0.083), not this EPA DAF, and not a UF you stack on top of 0.75 scaling.

HED/HEC recap (Chapters 11–12) without rerunning those chapters

You already converted inhalation concentrations with RfC dosimetry in section 11.3 : regional gas dose ratio (RGDR) or particle regional deposited dose ratio , Category 1 portal-of-entry gases versus Category 2/3 systemic gases, producing an HEC in mg/m³ . You already converted drug NOAELs with FDA 2005 mg/m² (0.67) in section 12.3 for maximum recommended starting dose . This chapter’s job is the UF that remains after those conversions, and the EPA oral 0.75 path that Chapter 12 did not use for first-in-human arithmetic.

Rules of thumb:

If the PoD is already an HED or HEC from default dosimetry, residual UFA is typically 3, not 10.

If a PBPK model produced the HED by matching the relevant internal metric, UFAK (TK) = 1 ; decide UFAD from TD data or leave the TD default.

Portal-of-entry / local GI corrosion is not a systemic metabolic-rate problem. Do not apply oral BW^0.75 as if clearance scaled the effect. Use the local PoD and a full UFA of 10 unless you have local dosimetry.

Human PoD: UFA = 1. Still apply UFH unless the human dataset already includes the sensitive subgroup the RfD must cover.

Do not run 0.67 FIH HED and 0.75 RfD HED on the same line and average them.

Scenario

A 90-day rat oral study, BMDL10 12 mg/kg-day for a systemic liver enzyme pattern, no PBPK, no developmental study. Assessor A applies EPA 2011 DAF 0.24 , HED = 12 × 0.24 = 2.88 mg/kg-day , then UFA = 3 , UFH = 10 , UFS = 10 (subchronic), UFD = 3 . Two 3s plus two 10s: EPA-style composite 1,000 (3 × 3 recorded as 10, times 10 × 10). RfD = 2.88 / 1,000 = 0.0029 mg/kg-day . Assessor B skips the DAF, uses UFA = 10 , UFH = 10 , UFS = 10 , UFD = 10 = 10,000 , and reports 12/10,000 = 0.0012 mg/kg-day . Assessor B piled four full tens. EPA 2002 practice would question whether an RfD should be derived , or would collapse to 3,000 , not celebrate 10,000 as “more conservative, therefore better.” Assessor C has a PBPK HED of 4.0 mg/kg-day matching AUC of the parent and in vitro TD showing equal hepatocyte sensitivity: UFAK = 1 , UFAD = 1 , UFH = 10 , UFS = 10 , UFD = 3 → 300, RfD = 4.0/300 = 0.013 mg/kg-day . Three lawful-looking numbers; the examination asks which factors were already spent in the PoD.

A second file is forestomach irritation in rodents after gavage of a corrosive. Applying BW^0.75 because “EPA 2011 says so for oral” treats a local effect as a systemic clearance problem.

Traps

Adding UFs (10 + 10 + 3) instead of multiplying.

Applying UFA = 10 after a default HED/HEC .

Using IPCS 4 × 2.5 and EPA 3 × 3 as if they were the same numerals.

Treating 3,000 as a legal maximum written into the US Code.

Using FDA 0.67 / Km 0.16 inside an IRIS oral RfD as the 2011 DAF, or the reverse in an FIH protocol.

Taking UFL = 10 on a BMDL .

Shrinking UFH because the workers in a small plant study “looked healthy.”

Applying BW^0.75 to a portal-of-entry lesion.